|
1
|
Cellini F and Valentini V: Current
perspectives on preoperative integrated treatments for locally
advanced rectal cancer: A review of agreement and controversies.
Oncology (Williston Park). 26:730–735. 2012.PubMed/NCBI
|
|
2
|
Valentini V, Glimelius B, Haustermans K,
Marijnen CA, Rödel C, Gambacorta MA, Boelens PG, Aristei C and van
de Velde CJ: EURECCA consensus conference highlights about rectal
cancer clinical management: The radiation oncologist's expert
review. Radiother Oncol. 110:195–198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Julien LA and Thorson AG: Current
neoadjuvant strategies in rectal cancer. J Surg Oncol. 101:321–326.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kapiteijn E, Marijnen CA, Nagtegaal ID,
Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B,
van Krieken JH, et al: Preoperative radiotherapy combined with
total mesorectal excision for resectable rectal cancer. N Engl J
Med. 345:638–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JC, Kim TW, Kim JH, Yu CS, Kim HC,
Chang HM, Ryu MH, Park JH, Ahn SD, Lee SW, et al: Preoperative
concurrent radiotherapy with capecitabine before total mesorectal
excision in locally advanced rectal cancer. Int J Radiat Oncol Biol
Phys. 63:346–353. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lim SH, Chua W, Henderson C, Ng W, Shin
JS, Chantrill L, Asghari R, Lee CS, Spring KJ and de Souza P:
Predictive and prognostic biomarkers for neoadjuvant
chemoradiotherapy in locally advanced rectal cancer. Crit Rev Oncol
Hematol. 96:67–80. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuremsky JG, Tepper JE and McLeod HL:
Biomarkers for response to neoadjuvant chemoradiation for rectal
cancer. Int J Radiat Oncol Biol Phys. 74:673–688. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maas M, Nelemans PJ, Valentini V, Das P,
Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R,
Haustermans K, et al: Long-term outcome in patients with a
pathological complete response after chemoradiation for rectal
cancer: A pooled analysis of individual patient data. Lancet Oncol.
11:835–844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fokas E, Liersch T, Fietkau R, Hohenberger
W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S, et
al: Tumor regression grading after preoperative chemoradiotherapy
for locally advanced rectal carcinoma revisited: Updated results of
the CAO/ARO/AIO-94 Trial. J Clin Oncol. 32:1554–1562. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rödel C, Martus P, Papadoupolos T, Füzesi
L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R,
Sauer R and Wittekind C: Prognostic significance of tumor
regression after preoperative chemoradiotherapy for rectal cancer.
J Clin Oncol. 23:8688–8696. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garcia-Aguilar J, de Anda E Hernandez,
Sirivongs P, Lee SH, Madoff RD and Rothenberger DA: A pathologic
complete response to preoperative chemoradiation is associated with
lower local recurrence and improved survival in rectal cancer
patients treated by mesorectal excision. Dis Colon Rectum.
46:298–304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Slaby O, Svoboda M, Michalek J and Vyzula
R: MicroRNAs in colorectal cancer: Translation of molecular biology
into clinical application. Mol Cancer. 8:1022009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Riordan AM, Thomas MK, Ronnekleiv-Kelly S,
Warner T, Geiger PG and Kennedy GD: Utility of micro-ribonucleic
acid profile for predicting recurrence of rectal cancer. J Surg
Res. 177:87–92. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mestdagh P, van Vlierberghe P, De Weer A,
Muth D, Westermann F, Speleman F and Vandesompele J: A novel and
universal method for microRNA RT-qPCR data normalization. Genome
Biol. 10:R642009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nugent M, Miller N and Kerin MJ: MicroRNAs
in colorectal cancer: Function, dysregulation and potential as
novel biomarkers. Eur J Surg Oncol. 37:649–654. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eriksen AH, Andersen RF, Pallisgaard N,
Sørensen FB, Jakobsen A and Hansen TF: MicroRNA expression
profiling to identify and validate reference genes for the relative
quantification of microRNA in rectal cancer. PLoS One.
11:e01505932016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eriksen AH, Andersen RF, Nielsen BS,
Sorensen FB, Appelt AL, Jakobsen A and Hansen TF: Intratumoral
heterogeneity of MicroRNA expression in rectal cancer. PloS One.
11:e01569192016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Drebber U, Lay M, Wedemeyer I, Vallböhmer
D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP
and Odenthal M: Altered levels of the onco-microRNA 21 and the
tumor-supressor microRNAs 143 and 145 in advanced rectal cancer
indicate successful neoadjuvant chemoradiotherapy. Int J Oncol.
39:409–415. 2011.PubMed/NCBI
|
|
20
|
Li T, Leong MH, Harms B, Kennedy G and
Chen L: MicroRNA-21 as a potential colon and rectal cancer
biomarker. World J Gastroenterol. 19:5615–5621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Slaby O, Svoboda M, Fabian P, Smerdova T,
Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered
expression of miR-21, miR-31, miR-143 and miR-145 is related to
clinicopathologic features of colorectal cancer. Oncology.
72:397–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lopes-Ramos CM, Habr-Gama A, Bde S
Quevedo, Felicio NM, Bettoni F, Koyama FC, Asprino PF, Galante PA,
Gama-Rodrigues J, Camargo AA, et al: Overexpression of miR-21-5p as
a predictive marker for complete tumor regression to neoadjuvant
chemoradiotherapy in rectal cancer patients. BMC Med Genomics.
7:682014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B,
Gu J, Chen HY and Sun XF: Clinicopathological significance of
microRNA-31, -143 and -145 expression in colorectal cancer. Dis
Markers. 26:27–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laurila EM and Kallioniemi A: The diverse
role of miR-31 in regulating cancer associated phenotypes. Genes
Chromosomes Cancer. 52:1103–1113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Svoboda M, Holla L Izakovicova, Sefr R,
Vrtkova I, Kocakova I, Tichy B and Dvorak J: Micro-RNAs miR125b and
miR137 are frequently upregulated in response to capecitabine
chemoradiotherapy of rectal cancer. Int J Oncol. 33:541–547.
2008.PubMed/NCBI
|
|
26
|
Della Vittoria, Scarpati G, Falcetta F,
Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK,
D'Incalci M, De Placido S and Pepe S: A specific miRNA signature
correlates with complete pathological response to neoadjuvant
chemoradiotherapy in locally advanced rectal cancer. Int J Radiat
Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McShane LM, Altman DG, Sauerbrei W, Taube
SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC
Working Group on Cancer Diagnostics: Reporting recommendations for
tumor marker prognostic studies (REMARK). J Natl Cancer Inst.
97:1180–1184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jakobsen A, Mortensen JP, Bisgaard C,
Lindebjerg J, Hansen JW and Rafaelsen SR: Preoperative
chemoradiation of locally advanced T3 rectal cancer combined with
an endorectal boost. Int J Radiat Oncol Biol Phys. 64:461–465.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jakobsen A, Ploen J, Vuong T, Appelt A,
Lindebjerg J and Rafaelsen SR: Dose-effect relationship in
chemoradiotherapy for locally advanced rectal cancer: A randomized
trial comparing two radiation doses. Int J Radiat Oncol Biol Phys.
84:949–954. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jakobsen A, Mortensen JP, Bisgaard C,
Lindebjerg J, Rafaelsen SR and Bendtsen VO: A COX-2 inhibitor
combined with chemoradiation of locally advanced rectal cancer: A
phase II trial. Int J Colorectal Dis. 23:251–255. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mandard AM, Dalibard F, Mandard JC, Marnay
J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P and Samama
G: Pathologic assessment of tumor regression after preoperative
chemoradiotherapy of esophageal carcinoma. Clinicopathologic
correlations. Cancer. 73:2680–2686. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bouzourene H, Bosman FT, Seelentag W,
Matter M and Coucke P: Importance of tumor regression assessment in
predicting the outcome in patients with locally advanced rectal
carcinoma who are treated with preoperative radiotherapy. Cancer.
94:1121–1130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Habr-Gama A, Perez RO, Nadalin W, Sabbaga
J, Ribeiro U Jr, e Sousa AH Silva Jr, Campos FG, Kiss DR and
Gama-Rodrigues J: Operative versus nonoperative treatment for stage
0 distal rectal cancer following chemoradiation therapy: Long-term
results. Ann Surg. 240:711–718. 2004.PubMed/NCBI
|
|
34
|
Habr-Gama A, Gama-Rodrigues J, São Julião
GP, Proscurshim I, Sabbagh C, Lynn PB and Perez RO: Local
recurrence after complete clinical response and watch and wait in
rectal cancer after neoadjuvant chemoradiation: Impact of salvage
therapy on local disease control. Int J Radiat Oncol Biol Phys.
88:822–828. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maas M, Beets-Tan RG, Lambregts DM,
Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef
M, Leijtens JW, et al: Wait-and-see policy for clinical complete
responders after chemoradiation for rectal cancer. J Clin Oncol.
29:4633–4640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Appelt AL, Pløen J, Harling H, Jensen FS,
Jensen LH, Jørgensen JC, Lindebjerg J, Rafaelsen SR and Jakobsen A:
High-dose chemoradiotherapy and watchful waiting for distal rectal
cancer: A prospective observational study. Lancet Oncol.
16:919–927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Habr-Gama A, De Souza PM, Ribeiro U Jr,
Nadalin W, Gansl R, Sousa AH Jr, Campos FG and Gama-Rodrigues J:
Low rectal cancer: Impact of radiation and chemotherapy on surgical
treatment. Dis Colon Rectum. 41:1087–1096. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ryan R, Gibbons D, Hyland JM, Treanor D,
White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D and
Sheahan K: Pathological response following long-course neoadjuvant
chemoradiotherapy for locally advanced rectal cancer.
Histopathology. 47:141–146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lindebjerg J, Rafaelsen S, Pløen J and
Jakobsen A: Step-sectioning of paraffin block from ‘completely
regressed’ rectal carcinoma after preoperative chemorediation. Ann
Oncol. 2009.PubMed/NCBI
|
|
40
|
Schneider PM, Baldus SE, Metzger R, Kocher
M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP,
Mueller RP and Hoelscher AH: Histomorphologic tumor regression and
lymph node metastases determine prognosis following neoadjuvant
radiochemotherapy for esophageal cancer: Implications for response
classification. Ann Surg. 242:684–692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bandres E, Arias F, Guerrero D, Lopez I,
Gonzalez-Huarriz M, Dorronsoro ML Gomez, Montes M, Monzon F, Torrea
N, Armendariz P and Balen E: Association between a specific miRNA
signature and pathological response to neoadjuvant
chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC)
patients. ASCO. e14057. 2012.
|
